TriGemX Bio To Go Public Through Merger With TCGX Acquisition, Plans Nasdaq Listing Under TGEM; Upon Closing, Combined Company Expected to Receive ~$246M Of Gross Proceeds
Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 millionTriGemX Bio, a biotechnology company focused on developing
TriGemX Bio is joining with another company to become public. This means investors are betting the biotech company has promising medicine projects ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.